Satellos Bioscience Inc. (MSCLF) Form 6-K — Aug 13, 2026
Satellos Bioscience (NASDAQ: MSLE) reported a Q2 2026 net loss of $11.7 million, or $0.56 per share, versus a $5.6 million loss ($0.39 per share) in the year-ago quarter. The wider loss was driven primarily by R&D spending that more than doubled to $9.6 million as the company advances SAT-3247 through its BASECAMP and TRAILHEAD Phase 2 trials in Duchenne muscular dystrophy. The company held $61.8 million in cash, cash equivalents and short-term investments as of June 30, 2026, up from $27.7 million at year-end 2025, following a February 2026 public offering that raised $57.2 million gross ($51.9 million net). Management expects existing cash to fund operations through 2027.
Key figures
- Eps
- -$0.56 per share Q2 2026 (vs -$0.39 Q2 2025); -$1.09 for six months 2026
- Guidance
- Existing cash, cash equivalents and short-term investments expected sufficient to finance operations through 2027; BASECAMP Phase 2 pediatric DMD data on track for Q4 2026; planned IND filings for Phase 2 FSHD trial in 2H 2026
- Net Income
- -$11.7M for Q2 2026 (vs -$5.6M Q2 2025); -$21.5M for six months ended June 30, 2026 (vs -$11.7M prior year)
- Cash Position
- $61.8M in cash, cash equivalents and short-term investments at June 30, 2026 ($7.393M cash equivalents + $54.446M short-term investments), vs $27.7M at December 31, 2025
- Shares Offered
- February 2026 offering: 5,168,019 common shares at $10.10 plus 495,049 pre-funded warrants at $10.09999
- Rd Commitments
- $21.828M in R&D purchase commitments ($16.992M due within 1 year)
- Ga Expense Q2 2026
- $2.5M (vs $1.9M Q2 2025)
- Rd Expense Q2 2026
- $9.6M (vs $4.4M Q2 2025)
- Reverse Split Ratio
- 1-for-12 share consolidation completed January 27, 2026 (185,507,153 shares consolidated into 15,458,903)
- Accumulated Deficit
- $103.456M at June 30, 2026
- Total Assets June30 2026
- $65.8M (vs $31.9M at Dec 31, 2025)
- Weighted Avg Shares Q2 2026
- 20,831,350
- Gross Proceeds Feb2026 Offering
- $57.197M gross; $51.901M net of $5.296M costs
- Shares Outstanding As Of MDADate
- 21,216,439 common shares; 3,072,564 pre-funded warrants; 2,723,237 stock options
- Operating Cash Used Six Months2026
- $17.613M used in operating activities; $51.938M provided by financing
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.